JP2013241442A5 - - Google Patents

Download PDF

Info

Publication number
JP2013241442A5
JP2013241442A5 JP2013154361A JP2013154361A JP2013241442A5 JP 2013241442 A5 JP2013241442 A5 JP 2013241442A5 JP 2013154361 A JP2013154361 A JP 2013154361A JP 2013154361 A JP2013154361 A JP 2013154361A JP 2013241442 A5 JP2013241442 A5 JP 2013241442A5
Authority
JP
Japan
Prior art keywords
pul130
pul128
pul131
cmv
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013154361A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013241442A (ja
JP6274770B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2013241442A publication Critical patent/JP2013241442A/ja
Publication of JP2013241442A5 publication Critical patent/JP2013241442A5/ja
Application granted granted Critical
Publication of JP6274770B2 publication Critical patent/JP6274770B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013154361A 2006-06-07 2013-07-25 ワクチン中に薬剤標的として用いるサイトメガロウイルス表面タンパク質複合体 Active JP6274770B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US81168906P 2006-06-07 2006-06-07
US60/811,689 2006-06-07
US90254407P 2007-02-20 2007-02-20
US60/902,544 2007-02-20

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2009514365A Division JP5822433B2 (ja) 2006-06-07 2007-06-06 ワクチン中に薬剤標的として用いるサイトメガロウイルス表面タンパク質複合体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015247487A Division JP2016128418A (ja) 2006-06-07 2015-12-18 ワクチン中に薬剤標的として用いるサイトメガロウイルス表面タンパク質複合体

Publications (3)

Publication Number Publication Date
JP2013241442A JP2013241442A (ja) 2013-12-05
JP2013241442A5 true JP2013241442A5 (enExample) 2017-08-24
JP6274770B2 JP6274770B2 (ja) 2018-02-07

Family

ID=38832360

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2009514365A Active JP5822433B2 (ja) 2006-06-07 2007-06-06 ワクチン中に薬剤標的として用いるサイトメガロウイルス表面タンパク質複合体
JP2013154361A Active JP6274770B2 (ja) 2006-06-07 2013-07-25 ワクチン中に薬剤標的として用いるサイトメガロウイルス表面タンパク質複合体
JP2015247487A Pending JP2016128418A (ja) 2006-06-07 2015-12-18 ワクチン中に薬剤標的として用いるサイトメガロウイルス表面タンパク質複合体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2009514365A Active JP5822433B2 (ja) 2006-06-07 2007-06-06 ワクチン中に薬剤標的として用いるサイトメガロウイルス表面タンパク質複合体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015247487A Pending JP2016128418A (ja) 2006-06-07 2015-12-18 ワクチン中に薬剤標的として用いるサイトメガロウイルス表面タンパク質複合体

Country Status (5)

Country Link
US (5) US7704510B2 (enExample)
EP (2) EP3031469B1 (enExample)
JP (3) JP5822433B2 (enExample)
CA (1) CA2654563A1 (enExample)
WO (1) WO2007146024A2 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3031469B1 (en) 2006-06-07 2023-08-23 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
US7947274B2 (en) 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
JP2010526787A (ja) * 2007-05-11 2010-08-05 ワクチン プロジェクト マネジメント ゲーエムベーハー Ｈｃｍｖ粒子を含有する組成物
US9439960B2 (en) 2007-10-10 2016-09-13 The Trustees Of Princeton University Cytomegalovirus vaccines and methods of production
WO2009114560A2 (en) * 2008-03-10 2009-09-17 Spaltudaq Corporation Compositions and methods for the therapy and diagnosis of cytomegalovirus
US8124093B2 (en) 2008-07-16 2012-02-28 Institute For Research In Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof
JP5475774B2 (ja) * 2008-07-16 2014-04-16 インスティテュート フォー リサーチ イン バイオメディシン ヒトサイトメガロウイルス中和抗体およびその使用
AU2013202419B2 (en) * 2008-07-16 2014-11-27 Institute For Research In Biomedicine Human cytomegalovirus neutralizing antibodies and uses thereof
AU2012203417B2 (en) * 2008-07-16 2014-07-10 Institute For Research In Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof
US8580276B2 (en) 2009-06-05 2013-11-12 City Of Hope Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof
WO2011057124A1 (en) * 2009-11-06 2011-05-12 Transtarget, Inc. Polyclonal bispecific antibody compositions and method of use
NZ600974A (en) 2009-12-23 2014-08-29 4Antibody Ag Binding members for human cytomegalovirus
RS54489B1 (sr) 2010-07-06 2016-06-30 Glaxosmithkline Biologicals Sa Lipozomi sa lipidima koji imaju poboljšanu pka vrednost za oslobađanje rnk
HUE047796T2 (hu) 2010-07-06 2020-05-28 Glaxosmithkline Biologicals Sa RNS bevitele több immunútvonal bekapcsolására
JP5940064B2 (ja) 2010-07-06 2016-06-29 ノバルティス アーゲー 低用量のｒｎａを用いた大型哺乳動物の免疫化
SMT202200311T1 (it) 2010-08-31 2022-09-14 Glaxosmithkline Biologicals Sa Liposomi pegilati per somministrare rna codificante un immunogene
EP2614072A4 (en) * 2010-09-09 2014-03-19 Univ Virginia Commonwealth VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
CN103313727B (zh) * 2010-09-29 2015-07-22 弗·哈夫曼-拉罗切有限公司 抗体组合物及使用方法
EP3520813B1 (en) 2010-10-11 2023-04-19 GlaxoSmithKline Biologicals S.A. Antigen delivery platforms
EP2667874A4 (en) * 2011-01-27 2014-07-30 Univ Princeton MTOR KINASE HEMMER AS ANTIVIRUS AGENT
EP3854413A1 (en) 2011-07-06 2021-07-28 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
TWI570240B (zh) * 2011-09-09 2017-02-11 默沙東公司 作為細胞巨大病毒疫苗之條件式複製ｃｍｖ
US20140348863A1 (en) * 2011-10-12 2014-11-27 Alessia Bianchi Cmv antigens and uses thereof
BR112014024023A2 (pt) * 2012-03-28 2017-07-18 Genentech Inc anticorpos idiotípicos anti-hcmv e usos dos mesmos
GB2513768B (en) 2012-07-06 2015-04-15 Novartis Ag Complexes of cytomegalovirus proteins and nucleic acids encoding such proteins
ES2719720T3 (es) * 2012-07-27 2019-07-12 Hope City Una vacuna de MVA para la administración de un complejo de UL128 y para prevenir la infección por CMV
CN109045294A (zh) * 2013-01-10 2018-12-21 思齐乐 流感病毒免疫原性组合物及其应用
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015170287A1 (en) * 2014-05-08 2015-11-12 Redvax Gmbh Means and methods for treating cmv
EP3015475A1 (en) 2014-10-31 2016-05-04 Novartis AG Mammalian cells expressing cytomegalovirus antigens
EP3048114A1 (en) 2015-01-22 2016-07-27 Novartis AG Cytomegalovirus antigens and uses thereof
CA3002922A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Human cytomegalovirus vaccine
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
CA3041307A1 (en) 2016-10-21 2018-04-26 Giuseppe Ciaramella Human cytomegalovirus vaccine
CA3050914A1 (en) * 2017-01-27 2018-08-02 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Vaccine compositions of herpesvirus envelope protein combinations to induce immune response
EP3612550B1 (en) 2017-04-19 2025-06-18 GlaxoSmithKline Biologicals S.A. Modified cytomegalovirus proteins and stabilized complexes
AU2018331874B2 (en) * 2017-09-13 2022-06-02 Sanofi Pasteur Human cytomegalovirus immunogenic composition
CN112512569A (zh) * 2018-05-11 2021-03-16 希望之城 表达多个巨细胞病毒(cmv)抗原的mva载体及其用途
MX2021004273A (es) 2018-10-17 2021-12-10 Glaxosmithkline Biologicals Sa Proteinas de citomegalovirus modificadas y complejos estabilizados.
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
WO2020208082A1 (en) * 2019-04-09 2020-10-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating cmv related diseases
EP4163378A4 (en) * 2020-06-09 2024-03-13 KM Biologics Co., Ltd. Fusion protein of pentamer and gb of cytomegalovirus, and vaccine containing said fusion protein
US11857622B2 (en) 2020-06-21 2024-01-02 Pfizer Inc. Human cytomegalovirus GB polypeptide
WO2022032177A1 (en) * 2020-08-06 2022-02-10 La Jolla Institute For Immunology Methods for treating and preventing cytomegalovirus infection
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
TWI843471B (zh) * 2022-03-11 2024-05-21 財團法人國家衛生研究院 含抗原和dna之組成物及其用途
WO2025231404A1 (en) * 2024-05-03 2025-11-06 The Trustees Of Princeton University Telomerase inhibition for treating or inhibiting herpesvirus infections

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267965B1 (en) * 1981-12-24 2001-07-31 Virogenetics Corporation Recombinant poxvirus—cytomegalovirus compositions and uses
WO2002066629A2 (en) * 2001-02-21 2002-08-29 Gabriele Hahn Recombinant vector containing infectious human cytomegalovirus genome with preserved wild-type characteristics of clinical isolates
DE10232322A1 (de) * 2002-07-16 2004-07-29 Hahn, Gabriele, Dr. Viral kodierte CxC determinieren den Gewebetropismus von HCMV
EP3031469B1 (en) * 2006-06-07 2023-08-23 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
GB0700133D0 (en) * 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof

Similar Documents

Publication Publication Date Title
JP2013241442A5 (enExample)
Ogembo et al. A chimeric EBV gp350/220-based VLP replicates the virion B-cell attachment mechanism and elicits long-lasting neutralizing antibodies in mice
CN116143938B (zh) 一种covid-19亚单位疫苗及其制备方法与应用
CN105792842B (zh) 埃巴病毒疫苗
JP6535133B2 (ja) 新規のバキュロウイルスベクター及び使用の方法
CN105073196B (zh) 呼吸道合胞病毒f蛋白表位
Mulama et al. A multivalent Kaposi sarcoma-associated herpesvirus-like particle vaccine capable of eliciting high titers of neutralizing antibodies in immunized rabbits
IE60671B1 (en) Monoclonal antiobodies to HIV and related peptides
CN103476788A (zh) 免疫原性屈曲病毒肽
WO2015181142A1 (en) Cytomegalovirus complexes and uses thereof
CN111996216B (zh) 腺相关病毒介导的新型冠状病毒抗体诱导物及疫苗组合物
US20230144060A1 (en) MERS-CoV VACCINE
Barasa et al. BALB/c mice immunized with a combination of virus-like particles incorporating Kaposi sarcoma-associated herpesvirus (KSHV) envelope glycoproteins gpK8. 1, gB, and gH/gL induced comparable serum neutralizing antibody activity to UV-inactivated KSHV
WO2020186687A1 (zh) 一种特异性结合四种血清型登革病毒的人源抗体
KR20240137110A (ko) 오미크론 코로나바이러스 백신 구조체 및 이를 제조하고 사용하는 방법
WO2023111725A1 (en) Sars-cov-2 vaccines
US20230227848A1 (en) Coronavirus vaccine constructs and methods of making and using same
Shen et al. DNA vaccine prime and replicating vaccinia vaccine boost induce robust humoral and cellular immune responses against MERS-CoV in mice
CN116490204A (zh) 催化失活血管紧张素转换酶2(ace2)变体及其用途
WO2021178844A1 (en) Zika and flavivirus immunogenic compositions and their use
CN116847881A (zh) 经改良的冠状病毒疫苗
CN100479858C (zh) 一种重组痘苗-sars疫苗及其制备方法
CN115975042B (zh) 一种β冠状病毒异源多聚体抗原、其制备方法和应用
Lee et al. Coronavirus nucleocapsid-based vaccine provides partial protection against hetero-species coronavirus in murine models
Mayer et al. The neutralizing capacity of antibodies elicited by parainfluenza virus infection of African Green Monkeys is dependent on complement